Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Transitional Cell

Explore clinical trials studying Carcinoma, Transitional Cell. Study availability and eligibility vary by location and protocol.

417 public trials 125 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Transitional Cell trial results

Completed

Patient-reported Outcomes in Bladder Cancer

NCT03584659

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • Aalborg University Hospital Aalborg, Denmark
  • Department of Oncology, Rigshospitalet Copenhagen, Denmark
  • Department of Oncology Herlev, Denmark
  • Odense University Hospital Odense, Denmark
View Trial Details
Completed

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • University of Arizona at Dignity Health St. Joseph's Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
  • Georgetown University Washington D.C., District of Columbia, United States
View all 28 locations
View Trial Details
Completed

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +2 more
Locations
  • Alaska Clinical Research Center, LLC Anchorage, Alaska, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
View all 161 locations
View Trial Details
Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +74 more
Locations
  • The University of Alabama Birmingham (UAB) Birmingham, Alabama, United States
  • Scottsdale Healthcare Hospitals DBA HonorHealth Scottsdale, Arizona, United States
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • Mount Sinai Medical Center of Florida, Inc. Miami, Florida, United States
View all 15 locations
View Trial Details
Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • Loma Linda University Loma Linda, California, United States
  • Providence Medical Institute Santa Monica, California, United States
View all 19 locations
View Trial Details
Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

NCT03232593

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +27 more
Locations
  • Dongnam Inst.of Radiological & Medical Sciences Busan, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Inje university Haeundae Paik Hospital Busan, South Korea
  • Dong-A University Hospital Busan, South Korea
View all 56 locations
View Trial Details

Related conditions